CSI-75

a potent and selective cathepsin S inhibitor; structure in first source

Also Known As:

1-methyl-6-(4-(2-(1-(oxazol-2-ylmethly)piperidin-4-yl)ethoxy)-3-(trifluoromethyl)phenyl)-1H-imidazo(4,5-c)pyridine-4-carbonitrile

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Baugh, Mark: 1 article (05/2011)
2.	Bennett, Jonathan: 1 article (05/2011)
3.	Black, Darcey: 1 article (05/2011)
4.	Boots, A Mieke H: 1 article (05/2011)
5.	Bruin, John: 1 article (05/2011)
6.	Cai, Jiaqiang: 1 article (05/2011)
7.	Claxton, Christopher: 1 article (05/2011)
8.	Dempster, Maureen: 1 article (05/2011)
9.	Gorecka, Monika: 1 article (05/2011)
10.	Grant, Ethan: 1 article (05/2011)

1.	Autoimmune Diseases (Autoimmune Disease) 05/01/2011 - "CSI-75 caused a significant reduction in disease score in both disease models, indicating a promising role for CatS inhibitors in the area of therapeutic treatments for autoimmune diseases."
2.	Multiple Sclerosis 05/01/2011 - "Therefore, CSI-75 was tested in a murine model of multiple sclerosis (i.e. "
3.	Rheumatoid Arthritis 05/01/2011 - "Finally, in a murine model with features resembling rheumatoid arthritis (the collagen-induced arthritis (CIA) model), CSI-75 was tested in a therapeutic manner (after disease development). "
4.	Experimental Arthritis 05/01/2011 - "Finally, in a murine model with features resembling rheumatoid arthritis (the collagen-induced arthritis (CIA) model), CSI-75 was tested in a therapeutic manner (after disease development). "